Follow us on social media
Home / Biohacking Academy / Growth Hormone
Growth HormoneEvidence: Clinical + preclinical

Pulses, not floods: understanding growth hormone secretagogues

Ipamorelin, CJC-1295, Sermorelin and Tesamorelin all aim at the same hormone through different doors. A guide to the GH axis and why pulsatility is the concept that matters most.

Listen to this articleAudio version
0:00 / 3:27
In this article
Key takeaways
  • Growth hormone is released in pulses, controlled by GHRH (stimulates), somatostatin (inhibits) and ghrelin (amplifies).
  • Secretagogues stimulate the body's own pulsatile release rather than replacing GH directly.
  • GHRH analogs and ghrelin-receptor agonists act on different receptors, which is why they are often studied together.

Growth hormone (GH) is not secreted at a steady rate. The pituitary releases it in bursts, most prominently during deep sleep, and this pulsatile pattern is part of how tissues read the signal. Growth hormone secretagogues are compounds that stimulate those pulses rather than supplying the hormone itself.

3Main regulators: GHRH, somatostatin, ghrelin
2Receptor classes targeted by secretagogues
IGF-1Main downstream readout of GH activity

The three regulators of the GH axis

  • GHRH (growth hormone–releasing hormone), from the hypothalamus, stimulates GH synthesis and release.
  • Somatostatin inhibits release, creating the troughs between pulses.
  • Ghrelin, acting on the GHS-R1a receptor, amplifies pulses and counteracts somatostatin.

GH then acts on the liver and other tissues to produce IGF-1, which mediates many of its growth and metabolic effects and feeds back to dampen further release.

Two classes of secretagogues

CompoundClassReported half-life
SermorelinGHRH analog (1–29)Minutes
TesamorelinStabilized GHRH analogUnder 1 hour
CJC-1295 + DACGHRH analog, albumin-bindingAbout 6–8 days
IpamorelinGHS-R1a agonist (ghrelin mimetic)About 2 hours

Ipamorelin: selectivity as a feature

Early ghrelin mimetics also raised cortisol and prolactin. Ipamorelin was described as the first selective GH secretagogue because, in animal studies, it released GH without significant increases in ACTH or cortisol, even at doses well above those needed for GH release . That selectivity is why it is often chosen in research designs that want to isolate the GH axis.

CJC-1295 and the DAC modification

Native GHRH and Sermorelin are cleared within minutes. CJC-1295 with DAC (Drug Affinity Complex) carries a reactive group that binds covalently to circulating albumin, dramatically extending its presence in the body. In healthy adults, a single administration produced sustained increases in GH and IGF-1, with an estimated half-life of roughly 6 to 8 days .

Tesamorelin and visceral fat

Tesamorelin is a stabilized GHRH analog that has been studied in randomized controlled trials. In patients with HIV-associated abdominal fat accumulation, it reduced visceral adipose tissue while preserving subcutaneous fat, alongside increases in IGF-1 . It is one of the most clinically characterized molecules in this class.

Secretagogues work with the body's rhythm instead of overriding it. That is both their appeal and the reason pulsatility belongs in every research design.

Why GHRH and ghrelin mimetics are studied together

Because GHRH analogs and GHS-R1a agonists act on different receptors, their effects on GH release can be synergistic: the GHRH signal drives the pulse while the ghrelin-like signal amplifies it and blunts somatostatin's brake. In research settings, IGF-1 is the most common integrated readout, since GH itself fluctuates too much for a single sample to be meaningful.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.
  2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
  3. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone–releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.

This article is for educational and research purposes only. Peptogen products are research-grade compounds intended exclusively for laboratory and in-vitro research. They are not for human or animal consumption, diagnostic or therapeutic use, and nothing here constitutes medical advice or dosing guidance.

Ipamorelin 10 mg vial
Related research compound

Ipamorelin 10 mg

$110 USD